| abstract |
The present disclosure relates to compositions and methods of treating cancer using chimeric antigen receptor (CAR) modified cells, methods and kits. Some embodiments of the present disclosure relate to isolated nucleic acid sequences encoding CARs. A CAR can include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3ΞΆ signaling domain. Antigen binding domains can bind antigens of non-essential organs. |